RxDoctor Payments DataLook up a doctor →

Ron Pitkanen, MD

Pain Medicine · Mountain Brk, ALNPI 1457677015

Payments from drug & device makers

$16,444in general payments, 2019–2025

Across 489 payments — averaging $33.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$13K
  • Collegium Pharmaceutical, Inc.$659
  • Vertos Medical, Inc.$363
  • Abbott$328
  • Almatica Pharma LLC$243
  • Scilex Pharmaceuticals Inc.$225
  • plus $1K from 26 others

What the payments were for

  • Consulting fees$1,60010%
  • Speaking & faculty fees$6,60040%
  • Travel & lodging$9416%
  • Food & beverage$7,28944%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,444 in reported general payments places this provider in the 95th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$381,134
Medicare patients
606
Services billed
2,679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl40$26,275
Xtampza ErOxycodone Myristate40$21,733
Buprenorphine76$18,503
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen722$16,339
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen507$13,031
Fentanyl67$5,341
Gabapentin424$5,001
Pregabalin209$4,798
Oxycodone Hcl121$2,210
Methocarbamol124$1,827
Morphine Sulfate ErMorphine Sulfate87$1,790
Tizanidine Hcl79$1,710
Lidocaine15$1,688
Hydromorphone Hcl93$1,408
Morphine Sulfate39$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$659$48,00880 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$20$18,962115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Mountain Brk

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →